Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TPMT | P51580 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 7/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4847985 | 0.87 | CASP6 (0.60) | CASP6TSHRLMNATPMTALDH1A1 | |
| SCHEMBL19436437 | 0.85 | PARP1 (0.49) | CASP6TSHRLMNAALDH1A1TTR | |
| SCHEMBL21808117 | 0.85 | GPR35 (0.41) | CASP6TSHRLMNAALDH1A1TTR | |
| SCHEMBL10756347 | 0.82 | CASP6 (0.55) | CASP6TSHRLMNATPMTALDH1A1 | |
| SCHEMBL30158739 | 0.82 | CASP6 (0.55) | CASP6TSHRLMNATPMTALDH1A1 | |
| SCHEMBL8841185 | 0.81 | CASP6 (0.62) | CASP6TSHRLMNATPMTALDH1A1 | |
| SCHEMBL18113036 | 0.81 | VCAM1 (0.49) | TPMTALDH1A1GAAMAPT | |
| SCHEMBL9706244 | 0.81 | TTR (0.62) | CASP6TSHRLMNATPMTALDH1A1 | |
| SCHEMBL2895332 | 0.81 | CASP6 (0.53) | CASP6TSHRLMNATPMTALDH1A1 | |
| SCHEMBL452336 | 0.81 | ALDH1A1 (0.58) | CASP6TSHRLMNATPMTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454524-B2 | (r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias | TERNS PHARMACEUTICALS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250276961-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | Terns, Inc. | 2025-09-04 | — | — | US | disclosed |
| EP-3919488-B1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2025-08-27 | — | — | EP | disclosed |
| US-20250243184-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | Terns, Inc. | 2025-07-31 | — | — | US | disclosed |
| CN-115448908-B | Compounds for the treatment of specific leukemias | 拓臻股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-115215838-B | Compounds for the treatment of specific leukemias | 拓臻股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-12240835-B2 | Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activity | TERNS PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| CN-118852164-A | PARP selective inhibitors | 轩竹生物科技股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240269305-A1 | STING AGONIST SUITABLE AS PAYLOAD OF ANTIBODY DRUG CONJUGATE | HITGEN INC (CN) | 2024-08-15 | — | — | US | disclosed |
| US-20240101536-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | TERNS PHARMACEUTICALS, INC. | 2024-03-28 | — | — | US | disclosed |
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016161145-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| EP-2661433-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | Novartis AG (CH) | 2013-11-13 | — | — | EP | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2012093101-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2012-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240835-B2 | Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activity | ABL1, BCR, ABL2 | CASP6 3260/4885TSHR 3775/4885LMNA 4130/4885 |
| US-20250276961-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | ABL1, ABL2, BCR | CASP6 3091/4885TSHR 4416/4885LMNA 4318/4885 |
| US-20250243184-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | ABL1, ABL2, BCR | CASP6 3091/4885TSHR 4416/4885LMNA 4318/4885 |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | CASP6 2888/4885TSHR 2475/4885LMNA 3778/4885 |
| US-12454524-B2 | (r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias | ABL1, ABL2, BCR | CASP6 4321/4885TSHR 3937/4885LMNA 3904/4885 |
| US-20240269305-A1 | STING AGONIST SUITABLE AS PAYLOAD OF ANTIBODY DRUG CONJUGATE | STING1, TBK1, CGAS | CASP6 2212/4885TSHR 2446/4885LMNA 1802/4885 |
| US-20240101536-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | ABL1, ABL2, BCR | CASP6 3091/4885TSHR 4416/4885LMNA 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.